Côd QR

Erlotinib Treatment in Colorectal Cancer Suppresses Autophagy Based on <i>KRAS</i> Mutation

The <i>KRAS</i> gene is mutated in approximately 45% of colorectal cancer patients. There are currently very few targeted treatments or therapies equipped to directly inhibit <i>KRAS</i> due to its unusual structural intricacies. Erlotinib, an EGFR inhibitor, has previously been demonstrated to redu...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Alexander Siegman, Aaron Shaykevich, Danbee Chae, Isaac Silverman, Sanjay Goel, Radhashree Maitra
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI AG 2024-07-01
Cyfres:Current Issues in Molecular Biology
Pynciau:
erlotinib
KRAS
autophagy
colorectal
cancer
EGFR
Mynediad Ar-lein:https://www.mdpi.com/1467-3045/46/7/447
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg